NCT06205953 A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
| NCT ID | NCT06205953 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
| Condition | AL Amyloidosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2024-01-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A prospective patients' registry collecting all new cases of AL amyloidosis evaluated at referral Centers from across Europe and a sample sharing network will be created to study mechanisms of the disease through the use of advanced molecular technologies and big data analysis tools.
Eligibility Criteria
Inclusion Criteria: * diagnosis of systemic AL amyloidosis; * treatment-naïve; * age ≥18 years; * ability to understand and willingness to sign an informed consent; * planned follow-up at participating center. Exclusion Criteria: * non-AL amyloidosis; * previous treatment for AL amyloidosis.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06205953 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying AL Amyloidosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06205953 currently recruiting?
Yes, NCT06205953 is actively recruiting participants. Contact the research team at segreteria.amiloidosi@smatteo.pv.it for enrollment information.
Where is the NCT06205953 trial being conducted?
This trial is being conducted at Heidelberg, Germany, Pavia, Italy, Utrecht, Netherlands, Pamplona, Spain and 2 additional locations.
Who is sponsoring the NCT06205953 clinical trial?
NCT06205953 is sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. The trial plans to enroll 400 participants.